Phase 2 Data For Ultra-Long-Acting Insulin Degludec Shows The Potential To Effectively Lower Blood Sugar, Including When Used Three Times A Week

Podiatry Arena Phase 2 Data For Ultra-Long-Acting Insulin Degludec Shows The Potential To Effectively Lower Blood Sugar, Including When Used Three Times A Week

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

Phase 2 Data For Ultra-Long-Acting Insulin Degludec Shows The Potential To Effectively Lower Blood Sugar, Including When Used Three Times A Week

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

10th July 2010, 04:00 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 10,134

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 22 Times in 22 Posts

Phase 2 Data For Ultra-Long-Acting Insulin Degludec Shows The Potential To Effectively Lower Blood Sugar, Including When Used Three Times A Week

Podiatry Arena members do not see these ads

Novo Nordisk presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA)...

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Switch to Linear Mode Switch to Hybrid Mode Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Phase III Trials Show Linagliptin Effectively Reduces Blood Glucose, With Good Tolerability	RSSFeedBot	Latest Diabetes Medicine Research & News	0	28th June 2010 10:30 AM
Novo Nordisk Starts Phase I Trial With Long-Acting Oral GLP-1 Analogue	RSSFeedBot	Latest Diabetes Medicine Research & News	0	13th January 2010 09:20 PM
New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions	RSSFeedBot	Latest Diabetes Medicine Research & News	0	16th October 2009 08:30 AM
Link Between Higher Blood Sugar Levels And Lower Brain Function In Diabetics, Study Shows	RSSFeedBot	Latest Diabetes Medicine Research & News	0	13th February 2009 05:30 AM
Newly Phase 3 Data Confirm Liraglutide Lowers Blood Sugar And Weight In Type 2 Diabetes Patients	RSSFeedBot	Latest Diabetes Medicine Research & News	0	8th February 2009 06:21 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 12:29 AM.

User Name		Remember Me?
Password